iSTAR Medical Advances MINIject® with Long-Term Glaucoma Results
iSTAR Medical's Remarkable Long-Term Results from the STAR-GLOBAL Trial
WAVRE, Belgium: iSTAR Medical, a leading medtech innovator dedicated to enhancing eye care solutions, has shared encouraging outcomes from its STAR-GLOBAL trial for the MINIject®. This groundbreaking device shows promising results in treating glaucoma over a significant five-year period, confirming the procedure's efficacy in managing intraocular pressure (IOP).
Significant Outcomes from the STAR-GLOBAL Trial
The STAR-GLOBAL trial, an extension of prior clinical investigations, highlights remarkable advancements made by iSTAR Medical. This extended study followed over five years of treatment with MINIject®, focusing on its safety and effectiveness in lowering IOP.
During this rigorous investigation, approximately 47 patients completed the trial, demonstrating that the MINIject® achieved an impressive 38% reduction in IOP. Furthermore, 83% of these participants experienced a greater than 20% decline in IOP from baseline measurements, with 80% of patients maintaining IOP levels of 18 mmHg or lower and 32% remaining medication-free.
Key Insights from Clinical Leaders
Dr. Karsten Klabe, a top surgeon and key investigator involved in the trial, expressed strong optimism about the five-year follow-up data. He underscored the confidence it instills regarding MINIject® as a reliable, long-term treatment option for glaucoma patients, assuring ongoing benefits well beyond the initial surgery.
Similarly, Andrew Tatham, a consultant ophthalmologist and advocate for glaucoma treatment advancements remarked on the outstanding results showcased by the MINIject®, echoing its consistent safety and efficiency when compared to previous trials. This longer-term effectiveness reinforces the trust placed in the MINIject® device.
The Unique MINIject® Device and Its Role in Glaucoma Management
As the only commercially available supraciliary micro-invasive glaucoma surgery (MIGS) implant, MINIject® provides a transformative approach to glaucoma management. By leveraging its unique porous structure and promoting natural fluid outflow, the device effectively reduces intraocular pressure while maintaining a strong safety profile.
Over 5,000 patients worldwide have already benefited from this innovative solution, making it a favored choice among healthcare professionals and patients alike.
Commitment to Advancing Glaucoma Treatment
With the end of its partnership with AbbVie, iSTAR Medical is now poised to progress MINIject® independently. The company aims to continue its journey, positioning the device as the gold standard for glaucoma treatments. The ongoing US STAR-V trial aims for FDA submission, further solidifying the MINIject® as a primary therapeutic option within the landscape of glaucoma care.
Conclusion and Future Directions
As iSTAR Medical forges ahead, its commitment to innovation and excellence in patient care remains unwavering. The insights gained from the STAR-GLOBAL trial will guide further research and development, ensuring that the MINIject® device continues to meet the pressing needs of glaucoma patients around the globe.
Frequently Asked Questions
What is the MINIject® device used for?
The MINIject® device is designed to treat glaucoma by lowering intraocular pressure (IOP) through a micro-invasive surgical procedure.
What were the results of the STAR-GLOBAL trial?
The trial indicated a sustained 38% reduction in IOP after five years, with 83% of patients seeing significant improvements and many remaining medication-free.
How many patients have undergone treatment with MINIject®?
Over 5,000 patients have been implanted with the MINIject® device globally, benefitting from its unique approach to managing glaucoma.
What does the future hold for MINIject®?
iSTAR Medical plans to submit for FDA approval of MINIject® by 2028 and will continue its commercial rollout in Europe and other regions.
Who were the main contributors to the STAR-GLOBAL trial?
Key contributions came from medical professionals like Dr. Andrew Tatham and Dr. Karsten Klabe, who provided critical insights into the efficacy and safety of the MINIject® device throughout the study.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.